June 2020. Volume 16. Number 2

Weak evidence in favour of hydroxychloroquina in COVID-19 patients

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Ag. 2020; [en prensa].

Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Complejo Asistencia de Zamora. Zamora. España.
2Servicio de Pediatría. Complejo Asistencial Universitario de Palencia. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 21/03/2020
Acceptance date: 22/03/2020
Publication date: 25/03/2020

Abstract

Authors’ conclusions: despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

Reviewers’ comment: the profile of patients in this study seems younger, of shorter evolution and milder than the group of patients expecting effective treatment at our hospitals. If the observed efficacy were reproduced in these patients, the treatment would be applicable in our setting. The effect size is high, although its clinical impact will depend on whether or not the virological clearance is associated with an improvement in clinical outcomes, such as respiratory failure or death. The quality of evidence is very low and the level of recommendation is weak in favor of the treatment.

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. Muy débil evidencia a favor de hidroxicloroquina en pacientes con COVID-19. Evid Pediatr. 2020;16:16.

AVC | Critically appraised articles

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Ag. 2020; [en prensa].

Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Complejo Asistencia de Zamora. Zamora. España.
2Servicio de Pediatría. Complejo Asistencial Universitario de Palencia. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 21/03/2020
Acceptance date: 22/03/2020
Publication date: 25/03/2020

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. Muy débil evidencia a favor de hidroxicloroquina en pacientes con COVID-19. Evid Pediatr. 2020;16:16.

25/03/2020

Linked Comment